Related references
Note: Only part of the references are listed.Lasmiditan for the treatment of migraine
Matilde Capi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development
Piero Barbanti et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Acute treatment of migraine: quo vadis?
Paolo Martelletti
EXPERT OPINION ON PHARMACOTHERAPY (2017)
The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine
Lars Edvinsson
HEADACHE (2017)
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michele Bally et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michele Bally et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies
Serena L. Orr et al.
HEADACHE (2016)
GBD 2015: migraine is the third cause of disability in under 50s
Timothy J. Steiner et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis
Chris Cameron et al.
HEADACHE (2015)
Emerging treatments for the primary headache disorders
Nathaniel M. Schuster et al.
NEUROLOGICAL SCIENCES (2015)
The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine
Uwe Reuter et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs
Peer C. Tfelt-Hansen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Anti-CGRP antibodies: a new approach to migraine prevention
Uwe Reuter
LANCET NEUROLOGY (2014)
Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
Paul B. Rizzoli
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Migraine - Established Concepts and New Developments
V. Speck et al.
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE (2013)
Examination of Unmet Treatment Needs Among Persons With Episodic Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study
Richard B. Lipton et al.
HEADACHE (2013)
In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
Eric D. Hostetler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Lasmiditan for acute migraine treatment
Lars Neeb et al.
FUTURE NEUROLOGY (2013)
LASMIDITAN HYDROCHLORIDE 5-HT1F Receptor Agonist Antimigraine Drug
U. Reuter et al.
DRUGS OF THE FUTURE (2012)
The cost of headache disorders in Europe: the Eurolight project
M. Linde et al.
EUROPEAN JOURNAL OF NEUROLOGY (2012)
Emerging treatment for chronic migraine and refractory chronic migraine
Luana Lionetto et al.
EXPERT OPINION ON EMERGING DRUGS (2012)
The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials
Peer C. Tfelt-Hansen et al.
JOURNAL OF HEADACHE AND PAIN (2012)
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Christopher J. L. Murray et al.
LANCET (2012)
Defining and refining 5-HT receptor targets for migraine
Andrew Charles
LANCET NEUROLOGY (2012)
Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study
Markus Farkkila et al.
LANCET NEUROLOGY (2012)
BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study
Hans-Christoph Diener et al.
CEPHALALGIA (2011)
Treatment of migraine: update on new therapies
Delphine Magis et al.
CURRENT OPINION IN NEUROLOGY (2011)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial
Michel D. Ferrari et al.
CEPHALALGIA (2010)
Zelrix™: A Novel Transdermal Formulation of Sumatriptan
Mark Pierce et al.
HEADACHE (2009)
New drugs for migraine
Lars Jacob Stovner et al.
JOURNAL OF HEADACHE AND PAIN (2009)
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W. Ho et al.
LANCET (2008)
Efficacy and safety of 1,000mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms
C. Lampl et al.
JOURNAL OF NEUROLOGY (2007)
The global burden of headache: a documentation of headache prevalence and disability worldwide
L. J. Stovner et al.
CEPHALALGIA (2007)
Migraine in the United States - Epidemiology and patterns of health care use
RB Lipton et al.
NEUROLOGY (2002)
Drug therapy: Migraine - Current understanding and treatment.
PJ Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment:: a meta-analysis of 53 trials
MD Ferrari et al.
LANCET (2001)
Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial
DJ Goldstein et al.
LANCET (2001)
Share Paper
